HIV Clinical Trial
The purpose of the study is to investigate the possible benefits of giving the anti-HIV drug
maraviroc to people who are taking darunavir/ritonavir alone for their HIV treatment. Many
people successfully take only darunavir/ritonavir treatment for their HIV. However, there
are some concerns that this treatment may not reach some areas of the body, such as the
brain and spinal cord (central nervous system or CNS), as effectively as it does the
bloodstream.
There is already a large clinical study looking at any differences between 'conventional'
HIV treatment with 3 drugs and single drug treatment with a protease inhibitor, also called
PI monotherapy, such as darunavir/ritonavir. This includes differences in the effects on the
CNS. However, this study will only be finished in 2013.
The investigators know that maraviroc can reach the CNS very effectively. The investigators
in this study will investigate the effect of adding maraviroc to darunavir/ritonavir
monotherapy by looking at levels of inflammation within the fluid that surrounds the CNS,
called cerebrospinal fluid or CSF.
Maraviroc is a licensed drug for the treatment of HIV treatment.. It showed good results in
2 clinical studies when it was taken by people whose HIV virus had developed resistance to
previous HIV treatments.
This study will also investigate safety as well as monitor effectiveness when patients take
maraviroc is taken on top of normal treatment of darunavir/ritonavir monotherapy.
Maraviroc has been shown to be present in the fluid that surrounds the brain in people
taking Maraviroc. It is not known if whether the presence of Maraviroc has any impact on
brain function. Therefore this study will also investigate brain (neurocognitive)
functioning with a computer test and some written tests.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
| Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
| Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
| Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
| Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
| Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
| Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
| Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
| Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
| Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
| Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
| Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
| Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
| Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
| Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
| Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
| Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
| Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
| Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |